Novel |
TSHR |
thyroid stimulating hormone receptor |
- Hormone ligand-binding receptors
- G alpha (s) signalling events
|
|
- Congenital nongoitrous hypothyroidism (CHNG)
|
Novel |
TTC3 |
tetratricopeptide repeat domain 3 |
|
|
|
Novel |
TYK2 |
tyrosine kinase 2 |
- Interleukin-6 signaling
- Interleukin-6 signaling
- MAPK3 (ERK1) activation
- MAPK1 (ERK2) activation
- Other interleukin signaling
- Interleukin-10 signaling
- Interleukin-4 and Interleukin-13 signaling
- IL-6-type cytokine receptor ligand interactions
- Interleukin-20 family signaling
- Interleukin-35 Signalling
- Interleukin-12 signaling
- Interleukin-12 signaling
- Interleukin-23 signaling
- Interleukin-23 signaling
- Interleukin-27 signaling
- Interleukin-27 signaling
- Interferon alpha/beta signaling
- Regulation of IFNA/IFNB signaling
- Regulation of IFNA/IFNB signaling
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Potential therapeutics for SARS
- Inactivation of CSF3 (G-CSF) signaling
- Inactivation of CSF3 (G-CSF) signaling
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Signaling by ALK fusions and activated point mutants
- Evasion by RSV of host interferon responses
|
- 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
- Ruxolitinib
- Tofacitinib
- Baricitinib
- Fostamatinib
- Abrocitinib
- Deucravacitinib
|
- Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
|
Novel |
USP6 |
ubiquitin specific peptidase 6 |
|
|
|
Novel |
VNN2 |
vanin 2 |
- Post-translational modification: synthesis of GPI-anchored proteins
- Vitamin B5 (pantothenate) metabolism
|
|
|
|
ABL1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
- Regulation of actin dynamics for phagocytic cup formation
- Role of ABL in ROBO-SLIT signaling
- Role of ABL in ROBO-SLIT signaling
- Myogenesis
- Myogenesis
- RHO GTPases Activate WASPs and WAVEs
- HDR through Single Strand Annealing (SSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Cyclin D associated events in G1
- RUNX1 regulates transcription of genes involved in differentiation of HSCs
- RUNX2 regulates osteoblast differentiation
- FCGR3A-mediated phagocytosis
- Factors involved in megakaryocyte development and platelet production
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
- Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
|
- ATP
- Imatinib
- Dasatinib
- N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
- Nilotinib
- XL228
- Bosutinib
- 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
- 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA
- Myristic acid
- PD-166326
- 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE
- 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide
- Regorafenib
- Ponatinib
- Fostamatinib
- Brigatinib
- Radotinib
- Asciminib
- Umbralisib
|
- Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
- Chronic myeloid leukemia (CML)
|
|
AGTR1 |
angiotensin II receptor type 1 |
- Peptide ligand-binding receptors
- G alpha (q) signalling events
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
|
- Valsartan
- Olmesartan
- Losartan
- Candesartan cilexetil
- Eprosartan
- Telmisartan
- Irbesartan
- Forasartan
- Saprisartan
- Tasosartan
- CYT006-AngQb
- Azilsartan medoxomil
- Fimasartan
- Angiotensin II
- Candesartan
|
|
|
ANKRD13C |
ankyrin repeat domain 13C |
|
|
|
|
BRCA1 |
BRCA1 DNA repair associated |
- Meiotic synapsis
- SUMOylation of DNA damage response and repair proteins
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- TP53 Regulates Transcription of DNA Repair Genes
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Neddylation
- Transcriptional Regulation by E2F6
- Meiotic recombination
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
- KEAP1-NFE2L2 pathway
- Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence
|
|
- Ovarian cancer
- Breast cancer
|
|
BTK |
Bruton tyrosine kinase |
- ER-Phagosome pathway
- MyD88:MAL(TIRAP) cascade initiated on plasma membrane
- Regulation of actin dynamics for phagocytic cup formation
- DAP12 signaling
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- G alpha (q) signalling events
- G alpha (12/13) signalling events
- MyD88 deficiency (TLR2/4)
- IRAK4 deficiency (TLR2/4)
- RHO GTPases Activate WASPs and WAVEs
- G beta:gamma signalling through BTK
- FCGR3A-mediated phagocytosis
- Potential therapeutics for SARS
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
- Dasatinib
- Inositol 1,3,4,5-Tetrakisphosphate
- XL418
- Ibrutinib
- Acalabrutinib
- Spebrutinib
- Fostamatinib
- Fenebrutinib
- Zanubrutinib
- Evobrutinib
- Tirabrutinib
- Abivertinib
- Branebrutinib
- Vecabrutinib
|
- Pituitary Dwarfism (PD); Isolated growth hormone deficiency (IGHD); Short Stature and Pituitary Defects (SSPD); Insulin-like growth factor 1 deficiency (IGFD)
- Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
|
|
CBR1 |
carbonyl reductase 1 |
- Synthesis of Prostaglandins (PG) and Thromboxanes (TX)
|
- Rutin
- Resveratrol
- Heptaethylene glycol
- 2-(2-{2-[2-(2-{2-[2-(2-Ethoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethanol, Polyethyleneglycol Peg400
- Quercetin
- 3-(4-Amino-1-Tert-Butyl-1h-Pyrazolo[3,4-D]Pyrimidin-3-Yl)Phenol
- Curcumin
- Curcumin sulfate
|
|
|
CCR1 |
C-C motif chemokine receptor 1 |
- Chemokine receptors bind chemokines
- G alpha (i) signalling events
- Interleukin-10 signaling
|
|
|
|
CCR5 |
C-C motif chemokine receptor 5 |
- Binding and entry of HIV virion
- Chemokine receptors bind chemokines
- G alpha (i) signalling events
- Interleukin-10 signaling
|
- Maraviroc
- AMD-070
- CCR5 mAb
- Leronlimab
- Aplaviroc
- Vicriviroc
- Ibalizumab
- INCB-9471
|
|
|
CISH |
cytokine inducible SH2 containing protein |
- Interleukin-7 signaling
- Neddylation
- Growth hormone receptor signaling
|
|
|
|
CSF2RB |
colony stimulating factor 2 receptor subunit beta |
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RAF/MAP kinase cascade
- Surfactant metabolism
- Defective CSF2RB causes SMDP5
- Defective CSF2RA causes SMDP4
- Interleukin receptor SHC signaling
|
- Sargramostim
- NPI 32101
- Resatorvid
|
|
|
CSF3R |
colony stimulating factor 3 receptor |
- Other interleukin signaling
- Transcriptional regulation of granulopoiesis
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Inactivation of CSF3 (G-CSF) signaling
- Inactivation of CSF3 (G-CSF) signaling
|
- Pegfilgrastim
- Filgrastim
- FavId
- Lenograstim
- Lipegfilgrastim
- Eflapegrastim
|
|
|
CXCR4 |
C-X-C motif chemokine receptor 4 |
- Binding and entry of HIV virion
- Signaling by ROBO receptors
- Chemokine receptors bind chemokines
- G alpha (i) signalling events
- Formation of definitive endoderm
- Specification of primordial germ cells
- Developmental Lineage of Multipotent Pancreatic Progenitor Cells
|
- Baclofen
- Framycetin
- AMD-070
- Plerixafor
- Ulocuplumab
- Ibalizumab
- MSX-122
|
- Chemokine receptor defect, including the following disease: WHIM syndrome
|
|
DAB1 |
DAB adaptor protein 1 |
- Reelin signalling pathway
|
|
|
|
DHX9 |
DExH-box helicase 9 |
- RIP-mediated NFkB activation via ZBP1
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- mRNA Splicing - Major Pathway
- PKR-mediated signaling
|
|
|
|
EIF2AK2 |
eukaryotic translation initiation factor 2 alpha kinase 2 |
- ISG15 antiviral mechanism
- Inhibition of PKR
- SUMOylation of immune response proteins
- Interferon alpha/beta signaling
- Evasion by RSV of host interferon responses
- PKR-mediated signaling
|
- Indomethacin
- H-89
- Fostamatinib
|
|